By December 2024, nearly 20 Chinese startups had become members of the Roche Accelerator initiative in China, working in a wide range of areas including novel biological mechanisms, platforms and drug modalities, molecular glues (small molecules that facilitate protein interactions), cyclic peptides, novel drug conjugates and RNA and cell therapies.
Roche Accelerator Deepens Pool Of Potential Chinese Partners
Roche's Shanghai-based Accelerator now includes close to 20 Chinese startups across multiple areas including novel modalities and AI-based research, fitting into the Swiss major's strategy of partnering in core areas to access innovation.
Read more by Xu Hu
More from China
More from Start-Ups & SMEs
• By
The Biovelocita II fund is supported by the likes of Amgen, Bristol Myers Squibb and Pfizer
• By
CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.
• By
The Singapore and Seattle-based biotech is joining the race to bring a ‘double whammy’ antibody-drug conjugate to patients.